Combination of Anti-CD40 and Anti-CD40L Antibodies as Co-Stimulation Blockade in Preclinical Cardiac Xenotransplantation
Martin Bender,Jan-Michael Abicht,Bruno Reichart,Elisabeth Neumann,Julia Radan,Maren Mokelke,Ines Buttgereit,Maria Leuschen,Felicia Wall,Sebastian Michel,Reinhard Ellgass,Stig Steen,Audrius Paskevicius,Andreas Lange,Barbara Kessler,Elisabeth Kemter,Nikolai Klymiuk,Joachim Denner,Antonia W. Godehardt,Ralf R. Tönjes,Jonathan M. Burgmann,Constança Figueiredo,Anastasia Milusev,Valentina Zollet,Neda Salimi-Afjani,Alain Despont,Robert Rieben,Stephan Ledderose,Christoph Walz,Christian Hagl,David Ayares,Eckhard Wolf,Michael Schmoeckel,Paolo Brenner,Uli Binder,Michaela Gebauer,Arne Skerra,Matthias Längin
DOI: https://doi.org/10.3390/biomedicines12081927
IF: 4.757
2024-08-24
Biomedicines
Abstract:The blockade of the CD40/CD40L immune checkpoint is considered essential for cardiac xenotransplantation. However, it is still unclear which single antibody directed against CD40 or CD40L (CD154), or which combination of antibodies, is better at preventing organ rejection. For example, the high doses of antibody administered in previous experiments might not be feasible for the treatment of humans, while thrombotic side effects were described for first-generation anti-CD40L antibodies. To address these issues, we conducted six orthotopic pig-to-baboon cardiac xenotransplantation experiments, combining a chimeric anti-CD40 antibody with an investigational long-acting PASylated anti-CD40L Fab fragment. The combination therapy effectively resulted in animal survival with a rate comparable to a previous study that utilized anti-CD40 monotherapy. Importantly, no incidence of thromboembolic events associated with the administration of the anti-CD40L PAS-Fab was observed. Two experiments failed early because of technical reasons, two were terminated deliberately after 90 days with the baboons in excellent condition and two were extended to 120 and 170 days, respectively. Unexpectedly, and despite the absence of any clinical signs, histopathology revealed fungal infections in all four recipients. This study provides, for the first time, insights into a combination therapy with anti-CD40/anti-CD40L antibodies to block this immune checkpoint.
biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy